Comprehensive Suicide Prevention Program for States
Forecast
Centers for Disease Control - NCIPC plans to offer grants of up to $1.2 million (at least $650,000) to any type of organization. It expects to make about 26 awards worth $118 million in total. It is a forecast: the notice is expected around February 16, 2027, with applications due around April 17, 2027.
From the official notice on Grants.gov, last changed July 27, 2026. Checked October 31, 2026.
- Award ceiling$1.2 million
- Award floor$650,000
- Expected awards26
- Total funding$118 million
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Forecast posted | July 27, 2026 |
|---|---|
| Expected posting | February 16, 2027 |
| Expected deadline | April 17, 2027 |
| Expected award date | August 15, 2027 |
Add the deadline to your calendar
Who can apply
This opportunity is open to any type of organization.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
The NOFO award floor is $650,000. The award ceiling is $1,200,000. CDC will consider applications less than $650,000 or more than $1,200,000 nonresponsive. They will receive no further review. Funding level and number of recipients will be based on availability of funds. Eligible applications must include the following to be responsive: 1. 1 Letter of Commitment (LOC) from state or territorial health department leadership, on official letterhead, endorsing the proposed activities and confirming the department's ability to carry them out.2. 1 Letter of Support (LOS) from the jurisdiction's suicide-related morbidity and mortality surveillance data system manager, on official letterhead, confirming data access, support identifying Focus Prevention Areas (FPAs), and willingness to collaborate on data sharing and analyses.3. 1 LOS from the jurisdiction's suicide-related syndromic surveillance data system manager, on official letterhead, confirming data access and support tracking near real-time nonfatal suicide-related outcomes, such as suicide attempts and suicidal ideation, that may be of public health significance.4. 3 LOS from partner organizations assisting with proposed activities, one for each tier: Tier 1: community-based interventions; Tier 2:healthcare-related interventions; Tier 3:structural interventions. Each letter must describe specific planned roles and contributions. General statements of support are nonresponsive.5. 2 LOS from multi-sector partners, such as AFSP chapters, suicide prevention coalitions, or organizations working with survivors or people personally affected by suicide. 6. 1 preliminary program organizational chart showing required staffing: 0.25 FTE program manager, 0.75 FTE epidemiologist, 0.5 FTE behavioral specialist, 0.5 FTE communications specialist, and 0.5 FTE evaluation specialist. Applicants must submit the LOC, LOS, preliminary DUA, and organizational chart as PDFs in Grants.gov using these filenames: "HealthDepartmentLeadership.LOC," "SuicideDataManager. LoS," "SyndromicDataManager. LoS," "Tier1Partner. LoS," "Tier2Partner. LoS," "Tier3Partner. LoS," "MultiSectorPartner1.LoS," "MultiSectorPartner2.LoS," and "Organizational Chart." Applications that do not meet these criteria will be considered nonresponsive and will not move forward for review.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This forecast is for CDC's Comprehensive Suicide Prevention Program for States, a cooperative agreement intended to support implementation and evaluation of a comprehensive public health approach to suicide prevention in the United States. Funded recipients will focus on one or more Focus Prevention Areas (FPAs), groups or settings identified through available data as experiencing a significant suicide burden, higher suicide morbidity or mortality rates or emerging suicide-related trends. Examples may include veterans, people living in rural areas, youth, older adults, men, and members of occupational groups at elevated risk, such as construction, agriculture and public safety workers. Recipients will use timely and relevant data to identify FPAs, understand contributors to suicide and suicidal behavior, monitor emerging trends, and guide prevention planning and response. Recipients will also assess existing suicide prevention programs and gaps in their jurisdiction, strengthen and coordinate multi-sector partnerships, select and implement complementary prevention strategies and approaches with the best available evidence from CDC's Suicide Prevention Resource for Action and communicate programmatic and surveillance findings, progress, successes and lessons learned to partners and other key audiences. The comprehensive approach is expected to include partnership development, data use, an asset and gap inventory, implementation of evidence-informed strategies or approaches, evaluation and communication activities. Recipients will evaluate their approach with a focus on continuous quality improvement, sustainability and measurable outcomes. Key outcomes include increased partner engagement, increased use of surveillance data for decision-making, improved coordination of comprehensive suicide prevention within the jurisdiction, reduced suicide risk factors and increased protective factors among selected FPAs, reduced suicide morbidity and a 5% reduction in suicide mortality among selected FPAs over the period of performance. Applications are not being solicited at this time. This forecast is provided to allow potential applicants time to begin planning, review relevant data, identify potential FPAs and consider partnerships and prevention strategies that may align with this anticipated opportunity.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to A.Philipose, CSP@cdc.gov, Refer to Email address.
Questions people ask
Who can apply for Comprehensive Suicide Prevention Program for States?
Centers for Disease Control - NCIPC accepts applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Comprehensive Suicide Prevention Program for States?
Expected deadline April 17, 2027. Confirm the date and time in the official notice on Grants.gov.
How much funding is available?
Awards of up to $1.2 million each. About $118 million in total across about 26 awards.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience